Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (23)

« Back to Publications

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Flaxman A. et al, (2021), The Lancet, 398, 981 - 990

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Frater J. et al, (2021), The Lancet HIV, 8, e474 - e485

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial

Clemens SC. et al, (2021)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Emary KRW. et al, (2021), The Lancet, 397, 1351 - 1362

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey M. et al, (2021), The Lancet, 397, 881 - 891

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478

Physiotherapy rehabilitation for osteoporotic vertebral fracture—a randomised controlled trial and economic evaluation (PROVE trial)

Barker KL. et al, (2020), Osteoporosis International, 31, 277 - 289

Exercise or manual physiotherapy compared with a single session of physiotherapy for osteoporotic vertebral fracture: three-arm PROVE RCT

Barker KL. et al, (2019), Health Technology Assessment, 23, 1 - 318

Storage of washed or irradiated red cells in AS‐7 improves their in vitro characteristics

Proffitt S. et al, (2015), Vox Sanguinis, 109, 203 - 213

Loss of Fibulin-2 Expression Is Associated with Breast Cancer Progression

Yi C-H. et al, (2007), The American Journal of Pathology, 170, 1535 - 1545

Metallothioneins and resistance to cisplatin and radiation in prostate cancer

Smith DJ. et al, (2006), Urology, 67, 1341 - 1347

Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer☆

Lewis TE. et al, (2005), Urologic Oncology: Seminars and Original Investigations, 23, 407 - 412

Load More